Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)

Background & Aims: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to non-significant, is a metric to evaluate the robustness of randomized controlled trials (RCTs)...

Full description

Bibliographic Details
Main Authors: Sabrina Sidali, Nanthara Sritharan, Claudia Campani, Jules Gregory, François Durand, Nathalie Ganne-Carrié, Maxime Ronot, Vincent Lévy, Jean-Charles Nault
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:JHEP Reports
Subjects:
Fragility index
Fragility quotient
p value
Hepatocellular carcinoma
Randomised controlled clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923000861

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923000861

Similar Items